Hanall Biopharma Co., Ltd.

Daewoong Pharmaceutical Co., Ltd.

Hyea Kyung Ahn

Eun Sun Kim

Sung Wuk Kim

Seung Kook Park

Jae Kap Jeong

Yeon Jung Song

Min Sun Kim

Dongok Shin

Hae-Young Yong

Tae Hyoung Yoo

Seung Wook Park

Sang Kyu Park

Seung Wook Lim

Yeo Wook Koh

Sang Myoung Ju

Woo Ik Chang

Hung Keun Lee

Joo Young Chung

Ji Soo Park

Shin Dongok

The present disclosure relates to an isolated anti-FcRn antibody, which is an antibody binding to FcRn (stands for neonatal Fc receptor, also called FcRP, FcRB or Brambell receptor) that is a receptor with a high affinity for IgG or a fragment thereof, a method of preparing thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune diseases using the antibody. The FcRn-specific antibody according to the present disclosure binds to FcRn non-competitively with IgG to reduce serum pathogenic auto-antibody levels, and thus can be used for the treatment of autoimmune diseases.

Antibody binding to FCRN for treating autoimmune diseases

Antibody binding to FcRn for treating autoimmune diseases

The present invention relates to new uses of modified human tumor necrosis factor receptor-1 (TNFRI) polypeptide, and more particularly, to uses thereof for prevention and treatment of dry eye syndrome. The modified TNFRI or modified TNFRI fragment of the present invention has excellent TNF&#x3b1; neutralizing activity, and inhibits TNF&#x3b1; activity on the ocular surface of the patient to suppress inflammation induction effects related to dry eye. Therefore, the modified TNFRI or modified TNFRI fragment of the present invention exhibits remarkable effects in the prevention and treatment of dry eye syndrome, and thus can be very useful in the prevention and treatment of dry eye syndrome.

Uses of modified human tumor necrosis factor receptor-1 polypeptide

The present invention relates to novel human thrombopoietin (hTPO) derivatives, and to process of preparation thereof. Particularly, sugar chains are introduced into native hTPO by substituting amino acids such as asparagine for amino acids at specific positions in native hTPO, preparing novel hTPO derivatives with high activities enhancing the platelet production in vivo. Therefore, the novel hTPO derivatives of this invention may be useful for the treatment of thrombocytopenia associated with anticancer therapy or the transplantation of bone marrow.

Human thrombopoietin comprising glycosylation sited at residues 157 and 164

Growing community of inventors

Gyeonggi-do, South Korea

Hyea Kyung Ahn